comparemela.com
Home
Live Updates
Concord Biotech rallies 8% as Kotak upgrades stock to add, sees 11% upside : comparemela.com
Concord Biotech rallies 8% as Kotak upgrades stock to 'add', sees 11% upside
After an impressive 220 bps EBITDA margin expansion in FY24, Concord is guiding for further improvement in FY25/26.
Related Keywords
Rakesh Jhunjhunwala ,
Ontario Inc ,
Concord Biotech ,
Kotak Institutional Equities ,
comparemela.com © 2020. All Rights Reserved.